Loading
A phase 2 trial of Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by STCube, Inc., now recruiting.
Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07306624 by STCube, Inc., with 62 participants planned, started 2026-01-10 and due to reach its primary completion in 2027-08-31. Interventions recorded: Nelmastobart and Docetaxel. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares STCube, Cytotoxic chemotherapy.
Shares Docetaxel, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/